Literature DB >> 10688795

Effects of environment on compensatory mutations to ameliorate costs of antibiotic resistance.

J Björkman1, I Nagaev, O G Berg, D Hughes, D I Andersson.   

Abstract

Most types of antibiotic resistance impose a biological cost on bacterial fitness. These costs can be compensated, usually without loss of resistance, by second-site mutations during the evolution of the resistant bacteria in an experimental host or in a laboratory medium. Different fitness-compensating mutations were selected depending on whether the bacteria evolved through serial passage in mice or in a laboratory medium. This difference in mutation spectra was caused by either a growth condition-specific formation or selection of the compensated mutants. These results suggest that bacterial evolution to reduce the costs of antibiotic resistance can take different trajectories within and outside a host.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10688795     DOI: 10.1126/science.287.5457.1479

Source DB:  PubMed          Journal:  Science        ISSN: 0036-8075            Impact factor:   47.728


  149 in total

1.  Divergence in fitness and evolution of drug resistance in experimental populations of Candida albicans.

Authors:  L E Cowen; L M Kohn; J B Anderson
Journal:  J Bacteriol       Date:  2001-05       Impact factor: 3.490

Review 2.  Mutation frequencies and antibiotic resistance.

Authors:  J L Martinez; F Baquero
Journal:  Antimicrob Agents Chemother       Date:  2000-07       Impact factor: 5.191

3.  Mutation frequency and biological cost of antibiotic resistance in Helicobacter pylori.

Authors:  B Björkholm; M Sjölund; P G Falk; O G Berg; L Engstrand; D I Andersson
Journal:  Proc Natl Acad Sci U S A       Date:  2001-11-20       Impact factor: 11.205

Review 4.  Evolution of drug resistance in Mycobacterium tuberculosis: clinical and molecular perspective.

Authors:  Stephen H Gillespie
Journal:  Antimicrob Agents Chemother       Date:  2002-02       Impact factor: 5.191

5.  Fitness cost of chromosomal drug resistance-conferring mutations.

Authors:  Peter Sander; Burkhard Springer; Therdsak Prammananan; Antje Sturmfels; Martin Kappler; Michel Pletschette; Erik C Böttger
Journal:  Antimicrob Agents Chemother       Date:  2002-05       Impact factor: 5.191

6.  Mutator bacteria as a risk factor in treatment of infectious diseases.

Authors:  Antoine Giraud; Ivan Matic; Miroslav Radman; Michel Fons; François Taddei
Journal:  Antimicrob Agents Chemother       Date:  2002-03       Impact factor: 5.191

7.  Use of mutator strains for characterization of novel antimicrobial agents.

Authors:  A J O'Neill; I Chopra
Journal:  Antimicrob Agents Chemother       Date:  2001-05       Impact factor: 5.191

8.  Models to understand the population-level impact of mixed strain M. tuberculosis infections.

Authors:  Rinat Sergeev; Caroline Colijn; Ted Cohen
Journal:  J Theor Biol       Date:  2011-04-16       Impact factor: 2.691

9.  Fitness cost and impaired survival in penicillin-resistant Streptococcus gordonii isolates selected in the laboratory.

Authors:  Marisa Haenni; Philippe Moreillon
Journal:  Antimicrob Agents Chemother       Date:  2007-11-12       Impact factor: 5.191

10.  Experimental adaptation of Salmonella typhimurium to mice.

Authors:  Annika I Nilsson; Elisabeth Kugelberg; Otto G Berg; Dan I Andersson
Journal:  Genetics       Date:  2004-11       Impact factor: 4.562

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.